PDE Inhibitors
SEE ALSO...
Items 61 to 70 of 84 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1,3-Dipropylxanthine | 31542-62-8 | sc-213513 | 50 mg | $320.00 | ||
1,3-Dipropylxanthine functions as a phosphodiesterase (PDE) inhibitor, exhibiting a distinctive binding profile that stabilizes the enzyme in an inactive conformation. Its unique molecular architecture facilitates strong π-π stacking interactions and van der Waals forces, which contribute to its selectivity. Kinetic studies indicate a competitive inhibition mechanism, where the compound effectively competes with natural substrates, leading to altered enzymatic turnover rates and prolonged signaling pathways. | ||||||
Cilomilast-d9 | 153259-65-5 (unlabeled) | sc-217896 | 1 mg | $380.00 | ||
Cilomilast-d9 acts as a phosphodiesterase (PDE) inhibitor, characterized by its ability to disrupt the enzyme's catalytic activity through allosteric modulation. Its structural features promote specific hydrogen bonding and hydrophobic interactions, enhancing binding affinity. Kinetic analyses reveal a non-competitive inhibition pattern, allowing it to modulate enzyme dynamics without directly competing with substrate binding, thereby influencing downstream signaling cascades. | ||||||
Roflumilast-d3 | 1189992-00-4 | sc-219987 | 1 mg | $380.00 | ||
Roflumilast-d3 functions as a phosphodiesterase (PDE) inhibitor, exhibiting unique selectivity for specific PDE isoforms. Its molecular architecture facilitates strong π-π stacking interactions and electrostatic attractions, which stabilize the enzyme-inhibitor complex. Kinetic studies indicate a mixed inhibition mechanism, where it alters both the affinity and maximum reaction rate of the enzyme, thereby fine-tuning cellular signaling pathways and modulating cyclic nucleotide levels effectively. | ||||||
Anagrelide-13C3 | sc-217646 | 1 mg | $490.00 | |||
Anagrelide-13C3 acts as a phosphodiesterase (PDE) inhibitor, characterized by its distinctive binding affinity to certain PDE isoforms. Its structural features promote hydrophobic interactions and hydrogen bonding, enhancing the stability of the enzyme-inhibitor complex. Kinetic analyses reveal a competitive inhibition profile, influencing substrate binding dynamics and altering the enzymatic turnover rate, which impacts cyclic nucleotide metabolism and downstream signaling cascades. | ||||||
Tadalafil-methyl-d3 | sc-220184 | 1 mg | $388.00 | |||
Tadalafil-methyl-d3 functions as a phosphodiesterase (PDE) inhibitor, exhibiting unique selectivity for specific PDE isoforms. Its molecular structure facilitates strong π-π stacking interactions and van der Waals forces, contributing to a robust enzyme-inhibitor complex. Kinetic studies indicate a non-competitive inhibition mechanism, affecting the catalytic efficiency and modulating cyclic nucleotide levels, thereby influencing various cellular signaling pathways. | ||||||
W-12, hydrochloride | 89108-46-3 | sc-203309 | 1 mg | $153.00 | ||
W-12, hydrochloride, acts as a phosphodiesterase (PDE) inhibitor, characterized by its ability to disrupt enzyme-substrate interactions through unique hydrogen bonding and hydrophobic interactions. Its structural conformation allows for effective steric hindrance, altering the enzyme's active site accessibility. Kinetic analyses reveal a mixed inhibition pattern, impacting both substrate affinity and turnover rates, thereby modulating intracellular signaling cascades with precision. | ||||||
Obscurolide A1 | 144397-99-9 | sc-203167 sc-203167A | 1 mg 5 mg | $210.00 $651.00 | ||
Obscurolide A1 functions as a phosphodiesterase (PDE) inhibitor, exhibiting distinctive molecular interactions that enhance its binding affinity. Its unique stereochemistry facilitates specific electrostatic interactions with the enzyme, leading to a conformational shift that stabilizes the inhibitor-enzyme complex. Kinetic studies indicate a non-competitive inhibition mechanism, effectively reducing the enzyme's catalytic efficiency while maintaining substrate binding, thus influencing cellular signaling pathways. | ||||||
BAY-60-7550 | 439083-90-6 | sc-396772 sc-396772A | 1 mg 5 mg | $165.00 $460.00 | 9 | |
BAY-60-7550 acts as a phosphodiesterase (PDE) inhibitor, characterized by its selective binding dynamics that disrupt enzyme activity. Its unique structural features allow for specific hydrophobic interactions, promoting a stable inhibitor-enzyme complex. Kinetic analysis reveals a mixed inhibition pattern, where it alters both the affinity for the substrate and the maximum reaction rate. This modulation of enzyme kinetics can significantly impact downstream signaling cascades. | ||||||
Icariin | 489-32-7 | sc-279198 sc-279198A sc-279198B | 1 g 5 g 10 g | $142.00 $413.00 $814.00 | ||
Icariin functions as a phosphodiesterase (PDE) inhibitor, exhibiting a distinctive ability to modulate cyclic nucleotide levels through competitive binding. Its molecular structure facilitates specific interactions with the enzyme's active site, enhancing selectivity. The compound demonstrates a unique allosteric effect, influencing enzyme conformation and altering substrate accessibility. This nuanced interaction profile contributes to its complex regulatory role in cellular signaling pathways. | ||||||
1-Methyl-4-nitro-5-propyl-1H-pyrazole-3-carboxamide | 247583-72-8 | sc-397129 | 10 mg | $330.00 | ||
1-Methyl-4-nitro-5-propyl-1H-pyrazole-3-carboxamide acts as a phosphodiesterase (PDE) inhibitor, characterized by its unique ability to disrupt cyclic nucleotide degradation. Its structural features allow for specific hydrogen bonding and hydrophobic interactions with the enzyme, leading to altered kinetic parameters. This compound exhibits a distinctive mechanism of action, potentially influencing downstream signaling cascades by stabilizing enzyme-substrate complexes and modulating enzyme activity. | ||||||